Daniel Strauss

• Assisted in data collection and analysis within R&D of NeuroSteer’s breakthrough EEG device.
• Tested the device on over 100 patients, collecting data to evaluate its predictive capability for neurodegenerative diseases.
• Followed the testing protocols and ensured appropriate handling of the device and quality assurance.
• Concluded a 92% predictability rate for Alzheimer's disease in diverse populations.

• Support data collection and setup of experimental protocols for clinical trials involving psychedelics.
• Manufacture lab-made psilocybin using genetically modified microorganisms
• Assist in statistical analysis and interpretation of results to explore therapeutic potential in mental health.

• Asses cases of academic integrity violations using a holistic approach.
• Facilitate conversations between the involved party and faculty to come to a clear resolution.
• Ensure a fair analysis of the case and the appropriate penalty.

Shadowed Shelly Keider, the Safety Lead in the Pharmacovigilance department of Takeda Israel.

• Learned the local safety processes and its implication to the global data bases.
• Reviewed adverse reactions, learned the parameters to assess causality and the process of reporting to the governing health authority.
• Reviewed the local health authority guidelines to ensure understanding of local compliance.
• Conducted a comparative safety analysis of Entyvio, including competitive medications, and presented to the safety team.

• Georgetown University Research Study- Safety and efficacy of involved-field SBRT for nodal oligorecurrent prostate cancer (Under the guidance of Dr. Malika Danner).
• Contributed to the understanding of targeted radiation therapy in prostate cancer management.
• Summarized key findings from existing literature on SBRT and nodal recurrences.
• Assisted in statistical analysis of patient outcomes.